Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patientsBECOUARN, Y; YCHOU, M; DUFFOUR, J et al.Journal of clinical oncology. 1998, Vol 16, Num 8, pp 2739-2744, issn 0732-183XArticle

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patientsSEITZ, J.-F; BENNOUNA, J; NASCA, S et al.Annals of oncology. 2002, Vol 13, Num 7, pp 1072-1079, issn 0923-7534Article

Combination raltitrexed (Tomudex®)-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesotheliomaFIZAZI, K; CALIANDRO, R; LE CHEVALIER, T et al.European journal of cancer (1990). 2000, Vol 36, Num 12, pp 1514-1521, issn 0959-8049Article

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinomaRINI, B; REDMAN, B; GARCIA, J. A et al.Annals of oncology. 2014, Vol 25, Num 9, pp 1794-1799, issn 0923-7534, 6 p.Article

Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal typeFANDI, A; BACHOUCHI, M; AZLI, N et al.Journal of clinical oncology. 2000, Vol 18, Num 6, pp 1324-1330, issn 0732-183XConference Paper

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatinDUCREUX, M; ROUGIER, P; FANDI, A et al.Annals of oncology. 1998, Vol 9, Num 6, pp 653-656, issn 0923-7534Article

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumorsGIACCONE, G; GONZALEZ-LARRIBA, J. L; FANDI, A et al.Annals of oncology. 2004, Vol 15, Num 5, pp 831-838, issn 0923-7534, 8 p.Article

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal typeHASBINI, A; MAHJOUBI, R; RAYMOND, E et al.Annals of oncology. 1999, Vol 10, Num 4, pp 421-425, issn 0923-7534Article

Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma typeFANDI, A; TAAMMA, A; AZLI, N et al.Head & neck. 1997, Vol 19, Num 1, pp 41-47, issn 1043-3074Article

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancerMASSARELLI, E; ANDRE, F; LIU, D. D et al.Lung cancer. 2003, Vol 39, Num 1, pp 55-61, issn 0169-5002, 7 p.Article

Undifferentiated nasopharyngeal cancer (UCNT) : current diagnostic and therapeutic aspectsALTUN, M; FANDI, A; DUPUIS, O et al.International journal of radiation oncology, biology, physics. 1995, Vol 32, Num 3, pp 859-877, issn 0360-3016Article

Nasopharyngeal cancer : epidemiology, staging, and treatmentFANDI, A; ALTUN, M; AZLI, N et al.Seminars in oncology. 1994, Vol 21, Num 3, pp 382-397, issn 0093-7754Article

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II studyFIZAZI, K; DOUBRE, H; LE CHEVALIER, T et al.Journal of clinical oncology. 2003, Vol 21, Num 2, pp 349-354, issn 0732-183X, 6 p.Article

Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal typeTAAMMA, A; FANDI, A; AZLI, N et al.Cancer. 1999, Vol 86, Num 7, pp 1101-1108, issn 0008-543XArticle

Carcinomes indifférenciées du nasopharynx : aspects épidémiologique, clinique et thérapeutique = Undifferentiated carcinoma of the nasopharynx. Epidemiological, clinical and therapeutical aspectsFANDI, A; YANES, B; TAAMMA, A et al.Bulletin du cancer. 1994, Vol 81, Num 7, pp 571-586, issn 0007-4551Article